RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018.
Fludeoxyglucose (18F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.
- Interesting? Share this article
Other news
Upcoming event
From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...
LinkedIn post Isologic goes electric
🔌Isologic Goes Electric! We are excited to announce the expansion of our electric fleet with the a...
First Patient Dosed with TLX250-CDx in Italy for ccRCC
The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...
![RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013](https://radboudtranslationalmedicine.nl/cdn/42251bd5-d9e6-4107-bbd7-ac13f0c8609a/-/smart_resize/250x170/-/format/auto/-/quality/smart/citryll-cityview-combined-logo.png){kind=logo}
RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013
Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...
Interested in a collaboration?
Contact us to discuss the possibilities.